1-(2,6-Dichlorophenyl)-2-indolinone
- CAS No.
- 15307-86-5
- Chemical Name:
- 1-(2,6-Dichlorophenyl)-2-indolinone
- Synonyms
- Diclofenac;Diciofenac;dichlofenac;DICLOFENAC FREE ACID;Pennsaid;Dichlofenac acid;Diclofenac (Aceclofenac EP Impurity A);Diclac;Rhumalgan;Voltaflan
- CBNumber:
- CB5225367
- Molecular Formula:
- C14H11Cl2NO2
- Molecular Weight:
- 296.15
- MOL File:
- 15307-86-5.mol
- MSDS File:
- SDS
- Modify Date:
- 2025/1/27 9:38:02
| Melting point | 156-158° |
|---|---|
| Boiling point | 412.0±45.0 °C(Predicted) |
| Density | 1.431±0.06 g/cm3(Predicted) |
| storage temp. | Sealed in dry,Room Temperature |
| solubility | soluble in Methanol |
| form | powder to crystal |
| pka | pKa 4 (Uncertain) |
| color | White to Almost white |
| Water Solubility | 1.278mg/L(30 ºC) |
| Merck | 14,3081 |
| InChIKey | DCOPUUMXTXDBNB-UHFFFAOYSA-N |
| CAS DataBase Reference | 15307-86-5(CAS DataBase Reference) |
| NIST Chemistry Reference | Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-(15307-86-5) |
| EPA Substance Registry System | Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (15307-86-5) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |    GHS06,GHS08,GHS09 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H301-H361d-H372-H411 | |||||||||
| Precautionary statements | P202-P260-P264-P270-P273-P301+P310 | |||||||||
| RIDADR | 3249 | |||||||||
| RTECS | AG6310000 | |||||||||
| HS Code | 2922.49.2600 | |||||||||
| HazardClass | 6.1(b) | |||||||||
| PackingGroup | III | |||||||||
| Hazardous Substances Data | 15307-86-5(Hazardous Substances Data) | |||||||||
| NFPA 704 |
|
1-(2,6-Dichlorophenyl)-2-indolinone Chemical Properties,Uses,Production
Uses
prostaglandin synthetic inhibitor
Indications
Diclofenac (Voltaren, Cataflam) is approved for use in rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, dysmenorrhea, and topically for the treatment treatment of ocular inflammation and actinic keratosis. Diclofenac exhibits approximately equal selectivity for COX-1 and COX-2. The most common adverse reactions are GI disturbances and headache.A reversible elevation of serum transaminases occurs in 15% of patients.
Biological Functions
Diclofenac (Voltaren) is a phenylacetic acid derivative that is a potent inhibitor of COX and that has analgesic, antiinflammatory, and antipyretic effects. Its use is accompanied by side effects similar to those of other NSAIDs. Indications for the drug include rheumatoid arthritis, osteoarthritis, and ophthalmic inflammation (use of an ophthalmic preparation).
Mechanism of action
Diclofenac is unique among the NSAIDs in that it possesses three possible mechanisms of action: 1) inhibition of the arachidonic acid cyclooxygenase system (3 to 1,000 times more potent than other NSAIDs on a molar basis), resulting in a decreased production of prostaglandins and thromboxanes; 2) inhibition of the lipoxygenase pathway, resulting in decreased production of leukotrienes, particularly the pro-inflammatory LKB4; and 3) inhibition of arachidonic acid release and stimulation of its reuptake, resulting in a reduction of arachidonic acid availability.
Pharmacokinetics
Diclofenac is rapidly and completely (～100%) absorbed on oral administration, with peak plasma levels being reached within 1.5 to 2.5 hours. The free acid (pKa = 4.0) is highly bound to serum proteins (99.5%), primarily albumin. Only 50 to 60% of an oral dose is bioavailable because of extensive hepatic metabolism.
Clinical Use
Diclofenac is synthesized from N-phenyl-2,6-dichloroaniline. It is available in 120 different countries and, perhaps, is the most widely used NSAID in the world. It was introduced in the United States in 1989 but was first marketed in Japan in 1974. It ranks among the top prescription drugs in the United States. Diclofenac possesses structural characteristics of both arylalkanoic acid and the anthranilic acid classes of anti-inflammatory drugs, and it displays anti-inflammatory, analgetic, and antipyretic properties.
Metabolism
Four major metabolites resulting from aromatic hydroxylation have been identified. The major metabolite via CYP3A4 is the 4′-hydroxy derivative and accounts for 20 to 30% of the dose excreted, whereas the 5-hydroxy, 3′-hydroxy, and 4′,5-dihydroxy metabolites via CYP2C9 account for 10 to 20% of the excreted dose. The remaining drug is excreted in the form of sulfate conjugates. Although the major metabolite is much less active than the parent compound, it may exhibit significant biological activity, because it accounts for 30 to 40% of all of the metabolic products.
1-(2,6-Dichlorophenyl)-2-indolinone Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| ANWITA APIS | +919000311012 | Hyderabad, India | 195 | 58 | Inquiry |
| Anant Pharmaceuticals Pvt Ltd | +91-8550986868 +91-9485998001 | Haryana, India | 460 | 58 | Inquiry |
| Chemicea Pharmaceuticals Pvt Ltd | +91-918482849343 +91-8482849343 | Mumbai, India | 461 | 58 | Inquiry |
| J S LABS | +91-7330612784 +91-7330612784 | Tamil Nadu, India | 159 | 58 | Inquiry |
| Refsyn Biosciences Pvt Ltd | +91-9488232275 +91-9488232274 | Tamil Nadu, India | 5 | 58 | Inquiry |
| Aarti Drugs Ltd (part of Aarti Group of Industries) | +91-2224019025 +91-9136988221 | Maharashtra, India | 57 | 58 | Inquiry |
| Vijaya Pharma And Life Science | +91-8939866271 +91-8939866271 | Tamil Nadu, India | 320 | 58 | Inquiry |
| Medec Dragon Private Limited | +91-9768474716 | Maharashtra, India | 59 | 58 | Inquiry |
| Amoli Organics Pvt Ltd | +91-2266214715 +91-9987040659 | Maharashtra, India | 36 | 58 | Inquiry |
| J.B. Chemicals Pharmaceuticals Ltd. | +91-022-24822222 +91-02224822222 | Mumbai, India | 10 | 58 | Inquiry |